Please login to the form below

Not currently logged in
Email:
Password:

Ex Sanofi boss joins Boston start-up

Chris Viehbacher joins other industry veterans as the newest board member of PureTech

Viehbacher 

After being ousted from Sanofi as its chief executive last year Chris Viehbacher has found a role as member of the board at a new Boston start-up.

Viehbacher, who spent six years at Sanofi until an apparent falling out with senior board members prompted his departure in October last year, will look to put his experience to good use at the newly founded biotech PureTech.

His move follows an aggressive fundraising campaign for the firm, which has raised $107m in just four months. 

“It is an honour to join this very dynamic and powerful group of both minds and personalities,” Viehbacher said in a statement. 

“PureTech's pipeline of companies is at an exciting inflection point, and I think the talent within the management team and board can achieve great things.”

Prior to taking the top job at Sanofi, he worked for GlaxoSmithKline for 20 years, and ultimately headed up its North America operations. 

He was one of several senior management staffers in-line to take GSK's top job, but ultimately lost out to Sir Andrew Witty in 2008, prompting his move to the French pharma rival. 

PureTech's board includes a number of other veterans from pharma companies such as Merck, Pfizer and Millennium Pharmaceuticals.

Among the 12 companies in PureTech's pipeline are Akili Interactive Labs, which is a collaboration between game designers and neuroscientists to spot signs of the onset of Alzheimer's disease and other neurological conditions.

Article by
Ben Adams

2nd March 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics